We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Serotonin in Parkinson's disease.
Behavioural Brain Research 2015 January 16
Parkinson's disease is a chronic neurodegenerative disorder characterized by the motor symptoms of bradykinesia, tremor, rigidity and postural instability. However, non-motor symptoms such as chronic fatigue, depression, dementia and sleep disturbances are also frequent and play a significant role with negative consequences in the quality of life of patients with Parkinson's disease. Although the progressive dopaminergic denervation is the cardinal pathology in the brains of patients with Parkinson's disease, others systems such as the serotonergic are affected as well. Over the last decade, several lines of evidence suggest that a progressive and non-linear loss of serotonergic terminals takes place in Parkinson's disease, though this is at a slower pace compared to the dopaminergic loss. Several studies have indicated that serotonergic dysfunction in Parkinson's disease is associated with the development of motor and non-motor symptoms and complications. Here, we aim to review the current evidence with regards to the serotonergic pathology in Parkinson's disease and its relevance to the development of clinical symptoms. We are primarily revising in vivo human studies from research with positron emission tomography molecular imaging.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app